Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly active as front-line induction in MM.

Original publication

DOI

10.1111/j.1365-2141.2008.06997.x

Type

Journal article

Journal

Br J Haematol

Publication Date

05/2008

Volume

141

Pages

512 - 516

Keywords

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Dexamethasone, Dose-Response Relationship, Drug, Doxorubicin, Female, Follow-Up Studies, Hematopoietic Stem Cell Mobilization, Humans, Male, Middle Aged, Multiple Myeloma, Peripheral Blood Stem Cell Transplantation, Pyrazines, Survival Analysis, Treatment Outcome